Ipamorelin

Think of it as a doorbell that genuinely rings. Press it and your pituitary really does answer with a burst of growth hormone. The problem is nobody has ever shown that anyone useful is home. We know the bell works in humans. We have no good evidence that ringing it makes you stronger, leaner or younger. The one time it was tested for a real job it didn't deliver.

Ipamorelin is a selective agonist of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a) on pituitary somatotrophs. Activating this Gq-coupled receptor triggers phospholipase-C signalling and calcium-dependent release of stored growth hormone, producing a GH pulse that subsequently raises IGF-1. Unlike non-selective GH-releasing peptides, it does so with minimal effect on cortisol, prolactin and appetite. It is administered parenterally because as a peptide it is not orally bioavailable.

Research contexts. Not proven uses, and not recommendations.

Genuine but limited. Early-phase human studies confirm ipamorelin raises endogenous growth hormone and is generally well tolerated, so its core biochemical action is real in humans. This puts it ahead of most grey-market peptides. The only controlled test of clinical benefit, a proof-of-concept Phase 2 study for postoperative ileus (NCT00672074, Helsinn; published 2014, approximately 117 patients), was negative on its primary endpoint and that indication did not advance. There are no controlled human trials demonstrating the muscle-building, fat-loss, recovery, sleep, skin or anti-ageing outcomes for which it is marketed. Proven to release GH in people. Not proven to do anything useful with it.

• !No proven clinical benefit in humans: its single controlled efficacy trial (postoperative ileus) was negative, and the popular fitness/anti-ageing uses are completely unstudied in humans.
• !Not an approved medicine anywhere; no marketing authorisation. In the UK it is an unlicensed substance sold as a 'research chemical' labelled 'not for human consumption' - a legal workaround, not a safety endorsement.
• !Grey-market product is unregulated: purity, sterility, peptide identity and dosing accuracy are not guaranteed, and contamination/endotoxin from non-pharmaceutical sources is a real injection risk.
• !Raising GH/IGF-1 is not consequence-free: theoretical and class-level concerns include fluid retention, joint pain, insulin resistance/raised blood glucose, and the general caution that chronically elevated IGF-1 may have implications for tumour growth - none of which has been characterised for long-term ipamorelin use in healthy people.
• !US compounding status has been unstable: ipamorelin acetate was placed on the FDA's interim 503A category-2 bulk drug substances list (significant safety concerns) in 2023, then removed in 2024 after the nomination was withdrawn, with the FDA subsequently recommending against its inclusion on the 503A bulks list - it has no settled legitimate route in the US either.
• !Marketing routinely overstates a clean GH boost as if it equals real-world physique or longevity benefits; that inferential leap is unsupported.

Not a licensed UK medicine and holds no MHRA marketing authorisation. It is an investigational compound whose only controlled clinical trial (in postoperative ileus) was negative and was not pursued further. It is not a controlled drug under the Misuse of Drugs Act, but selling or supplying it for human use without authorisation would breach the Human Medicines Regulations 2012. It is sold online as an unlicensed 'research chemical' labelled 'not for human consumption'. There is no legitimate UK prescription route for it.

• NCT00672074· Phase 2 (proof-of-concept)· Completed - negative; primary efficacy endpoint not met

  Safety and Efficacy of Ipamorelin for Management of Post-Operative Ileus

  Sponsor Helsinn Therapeutics; randomised, double-blind, placebo-controlled in bowel-resection patients (~117 enrolled). Primary endpoint (time to tolerance of a solid meal) showed no significant difference versus placebo; published Int J Colorectal Dis 2014.

1. 01
   Ipamorelin, the first selective growth hormone secretagogue — Raun K, Hansen BS, Johansen NL, Thogersen H, Madsen K, Ankersen M, Andersen PH, European Journal of Endocrinology (1998)

   Foundational paper describing ipamorelin's design and its defining GH-release selectivity (minimal ACTH/cortisol/prolactin), comparable to GHRH.

2. 02
   Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients — Beck DE, et al., International Journal of Colorectal Disease (2014)

   Published report of the Helsinn Phase 2 trial (NCT00672074); negative on the primary endpoint (time to tolerance of a solid meal), no significant difference versus placebo.

3. 03
   Growth hormone secretagogues: history, mechanism of action, and clinical development — Ishida J, et al., JCSM Rapid Communications (2020)

   Review placing ipamorelin within the GH secretagogue class and summarising clinical development status.

4. 04
   Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (interim 503A category-2 list) — US Food and Drug Administration, FDA (2024)

   Documents the FDA's evolving compounding stance; ipamorelin acetate was added to category 2 in 2023 and removed in 2024 after the nomination was withdrawn.